|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||273.376 g·mol−1|
|3D model (JSmol)|
Tropanserin (INN; MDL-72,422) is a drug which acts as a potent and selective 5-HT3 receptor antagonist. It was investigated in clinical trials for the treatment of migraine in the 1980s but was never marketed.
Tropanserin can be prepared by the reaction of tropine with 3,5-dimethylbenzoyl chloride.
- King FD, Jones BJ, Sanger GJ (22 October 1993). 5-Hydroxytryptamine-3 Receptor Antagonists. CRC Press. p. 244. ISBN 978-0-8493-5463-2. Retrieved 6 May 2012.
- Johnson G (1 August 1987). "Recent Advances in Migraine Research". In Bailey DM (ed.). Annual Reports in Medicinal Chemistry. 22. Academic Press. p. 44. doi:10.1016/S0065-7743(08)61153-7. ISBN 978-0-08-058366-2.
- US 4563465, Fozard JR, Gittos MW, "Treatment of migraine with substituted tropyl benzoate derivatives", issued 7 January 1986, assigned to Merrell Dow Pharma